SGLT-2 inhibitors and risk of 59 long-term health conditions, hospitalization, and mortality
Main finding · All-cause mortalityResult — go to the resultAdjusted hazard ratio 0.73 95% CI 0.71–0.75Authors' conclusion
SGLT-2i use in T2DM was associated with significant reductions in mortality, hospitalization, and MLTC burden.
Study context
- Population
- Adults aged ≥40 years with T2D, England (2012–2023)
- Participants
- 364,522 adults
- Comparison
- SGLT2i vs DPP-4i initiation
- Outcome
- All-cause mortality
Methodological detailstarget trial emulation, linked primary care, hospital and mortality records, weighted Cox proportional hazards and negative binomial regression, Benjamini-Yekutieli correction for multiple testing
- Target trial emulation
- Linked primary care, hospital and mortality records
- Weighted Cox proportional hazards and negative binomial regression
- Benjamini-Yekutieli correction for multiple testing
Main finding
As reported in the abstract
Adjusted hazard ratio
0.73
95% CI 0.71–0.75
P < 0.001
SGLT-2ivs DPP-4i
aHR 0.73 (95% CI 0.71–0.75); P < 0.001
Further findings
Incidence of 59 prespecified long-term conditions
- Reduced risks with SGLT2i, including dementia, cancer, MASLD, DFU, epilepsy and rheumatoid arthritis
- 28 conditions
- Increased risks with SGLT2i, including candidiasis and DKA
- four conditions
Safety
- Increased risks with SGLT2i, including candidiasis and DKA
- four conditions
Original publication
SGLT-2 inhibitors and risk of 59 long-term health conditions, hospitalization, and mortality. Eur J Endocrinol. Published 18 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →